Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: Survodutide, BI 456906
Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is administered as a once-weekly subcutaneous injection.
Sign in to rate this peptide.
Survodutide is a synthetic peptide dual agonist that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R activation augments glucose-dependent insulin release, delays gastric emptying, and suppresses appetite via central nervous system pathways, while GCGR activation increases hepatic fatty-acid oxidation, energy expenditure, and reduction of liver fat. This balanced co-agonism is designed to drive weight loss and resolve hepatic steatosis and inflammation, and fatty-acid acylation gives it a half-life suitable for weekly dosing.